AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00822575 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZapperClick
Description: The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
Study NCT00822575 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ZapperClick
Description: The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
Study NCT02490748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance
Study NCT02490748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Description: The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Study NCT00322361 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: RECOMBIVAX HB™
Description: RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
Study NCT00322361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Modified process Hepatitis B Vaccine
Description: Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
Study NCT02596217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-066
Description: SC injection
Study NCT02596217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-066
Description: IV infusion
Study NCT02596217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection (stage 1)
Study NCT02596217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion (stage 2)
Study NCT01414543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information Sheet
Description: Providing the Participant with information regarding the aim of the experiment
Study NCT01414543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Consent
Description: Providing a consent form for participants. The participant is aware of his or her rights
Study NCT01414543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: interview
Description: participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
Study NCT01414543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Debrief
Description: at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
Study NCT00598117 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~* Initial QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS
Study NCT00571571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Individual psychotherapy with parent collateral/psychoeducation as necessary.
Study NCT00571571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Psychotherapy
Description: Individual psychotherapy and family interventions (as needed)
Study NCT02515994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon C
Description: Investigational contact lens
Study NCT02515994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: Marketed Monthly Replacement Lens (Control)
Study NCT01634659 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses (DAILIES TOTAL1®)
Description: Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
Study NCT01634659 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)
Description: Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
Study NCT02703506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session of Pain Education programe
Description: Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
Study NCT02703506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
Study NCT00140530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (Taxus)
Description: patients has been implanted the Paclitaxel-eluting stent.
Study NCT00140530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin-eluting stent
Description: patients has been implanted the Rapamycin-eluting stent.
Study NCT04295343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Three-dimensional (3D) rectal water contrast transvaginal ultrasonography
Description: Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
Study NCT04295343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed colonography
Description: Computed colonography or virtual colonoscopy uses special x-ray equipment to examine the large intestine. During the exam, a small tube is inserted a short distance into the rectum to allow for inflation with gas while computed tomographic images of the colon and the rectum are taken.
Study NCT02057913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
Study NCT03782974 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beta glucan
Description: Following screening and enrollment, participants will be treated with 2 tablets (Proglucamune or placebo) per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
Study NCT03782974 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta glucan
Description: Following screening and enrollment, participants will be treated with 2 tablets (Proglucamune or placebo) per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
Study NCT02618694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior retroperitoneoscopic adrenalectomy
Description: Patient is in prone, half Jack-knife position, and hips and knees are fixed in 75-90°. A 15 mm trocar incision just below the tip 12th rib. Prepare a small retroperitoneal space with finger and insert two 5 mm trocars about 5 cm lateral and medial to the first trocar with digital guidance. Medial trocar will be inserted upward. Lateral one will be lateral and below the 11th rib. Dissect inferior to diaphragm and retraction of the kidney downward. Mobilize the adrenal gland. At right side, start medial and caudally. Control the adrenl arteries crossing the IVC posteriorly. Prepare adrenal vein posterolaterally. Control between two clips. Continue gland dissection laterally and cranially. At left side, prepare the adrenal vein between the gland and diaphragm medial to the upper pole of the kidney. Dissect medial, lateral and cranially. Retrieve the mass through middle incision. Insert a drain and close skin incisions (Walz M. K., 2005).
Study NCT02618694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperitoneal laparoscopic adrenalectomy
Description: On right side, patient is on supine position. Put a trocar at umbilicus for the camera. Put 4 trocars 1-2 cm subcostal from subxiphoid (10-12 mm) for liver retractor, to far lateral (5 mm) and two 10 mm trocars inbetween. Retract liver, incise the retroperitoneum, and identify right adrenal gland between upper pole of the kidney and IVC. Dissect gland from the kidney than laterally and posteriorly from the diaphragm. Expose, apply clips to, and divide the adrenal vein. On left side, patient is on lateral decubitus. Put a trocar at umbilicus for the camera, 4 trocars 1-2 cm subcostal from the midline to the far most lateral possible (the last is 5 mm the rest are 10 mm). Mobilize colon flexure and expose the kidney. Separate kidney from the pancreas and spleen. Mobilize the tumor, starting by posterior surface, superior border then from the renal surface. Divide the adrenal vein. Retrieve the mass (Suzuki, Tsuru, \& Ihara, 2012; Linos, 2005; George \& Kavoussi, 2010).
Study NCT02621658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear Liquid Diet
Description: Patients will be allowed to consume clear soft drinks like ginger ales, Sprite®, 7-Up®, Gatorade®, Kool Aid®. They can also have strained fruit juices like apple, white grape juice and lemonade, and water, tea and coffee without milk or non-dairy creamer. Patient in this arm will also be allowed to have low-sodium chicken or beef broth , in addition to non-red hard candies, Jell-O®, and popsicles.
Study NCT02621658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Liquid Diet
Description: Patients will be allowed to consume a Full Liquid Diet, including nutritional supplements(Ensure®, Boost®, Glucerna®), strained cereals(like cream of wheat or strained oatmeal) and vegetables, purred fruit without seeds or pulp, milk, plain ice cream or yogurt, sherbet, coffee with cream, and tea.
Study NCT02071602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD-NP
Description: Randomized 1:1:1
Study NCT02071602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD-NP
Description: Randomized 1:1:1
Study NCT02033200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stendra 200 mg
Study NCT02033200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stendra 200 mg
Study NCT02033200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02033200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03197870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778
Description: Subcutaneous AKB-9778 15mg
Study NCT00820820 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ROUVAX
Description: Measles vaccine (ROUVAX ®), Schwarz strain (>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
Study NCT00820820 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Vehicle (water for injection), 0.5 ml, once
Study NCT03197870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Placebo
Study NCT03197870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Placebo
Study NCT01432275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADC blood glucose meter
Description: Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.
Study NCT01432275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator blood glucose meter
Description: Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.
Study NCT01432275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADC blood glucose meter with insulin calculator active
Description: Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
Study NCT04601584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 4, GNR-084
Description: 4 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Study NCT04601584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 5, GNR-084
Description: 10 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Study NCT04601584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 6, GNR-084
Description: 20 ng/kg 6-hours intravenous infusion once a week; 4 doses per cycle, up to 5 cycles
Study NCT00040378 — intervention group
Intervention type: DRUG
Intervention: alphatocopherol
Description: 400 IU daily
Study NCT00040378 — intervention group
Intervention type: DRUG
Intervention: Selenium
Description: 200mcg daily
Study NCT00040378 — intervention group
Intervention type: DRUG
Intervention: Placebo replacement for vitamin E
Description: 1 placebo pill daily
Study NCT00040378 — intervention group
Intervention type: DRUG
Intervention: Placebo replacement for Selenium
Description: 1 placebo pill daily
Study NCT01805609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working with the Caregiving Family (WCF) training
Description: Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture \& discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff \& that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
Study NCT00504959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT04747951 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemoradiotherapy
Description: 50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d
Study NCT04747951 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy
Description: 50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d
Study NCT04747951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME
Description: Total mesorectal excision
Study NCT04747951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: Total mesorectal excision
Study NCT04747951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: consolidation chemotherapy
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 3 courses, 3 weeks per course
Study NCT04747951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles
Study NCT04747951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles
Study NCT02352987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neem plus propylene glycol plus salicylic acid
Description: Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
Study NCT02352987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salicylic acid
Description: salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
Study NCT00505661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg PO Once Daily
Study NCT01811836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
Study NCT00860041 — intervention group
Intervention type: BEHAVIORAL
Intervention: pain questionnaires
Study NCT00365209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00365209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00365209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Given orally
Study NCT01801241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomic TSA using IRI Instrumentation
Description: Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Intelligent Reusable Instrument (IRI) to transfer the pre-operative plan for glenoid implant positioning to the patient's anatomy.
Study NCT01801241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomic Total Shoulder Arthroplasty
Description: Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same in the two arms, with the exception of the tools used to place the guide pin for placement of the glenoid implant.
Study NCT01801241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic Total Shoulder Arthroplasty
Description: Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same in the two arms, with the exception of the tools used to place the guide pin for placement of the glenoid implant.
Study NCT02537834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofogliflozin
Study NCT02537834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 analogue
Study NCT05051800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Program to Support Coping and Communication in Families
Description: Parents and children will access online materials designed to support the use of effective ways to cope with the diagnosis and treatment of cancer and to support open and communication.
Study NCT05051800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Program to Support Coping and Communication in Families
Description: Parents and children will access online materials designed to support the use of effective ways to cope with the diagnosis and treatment of cancer and to support open and communication.
Study NCT02098616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
Study NCT02098616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325 + RBV
Description: Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day